Clarithromycin attenuates IL-13-induced periostin production in human lung fibroblasts

Respiratory Research

Volumn 18, Issue 1, 2017, Pages

  Komiya, Kosaku ^a,b,c,d   Ohta, Shoichiro ^a   Arima, Kazuhiko ^a   Ogawa, Masahiro ^a   Suzuki, Shoichi ^e   Mitamura, Yasutaka ^a   Nunomura, Satoshi ^a   Nanri, Yasuhiro ^a   Yoshihara, Tomohito ^a   Kawaguchi, Atsushi ^a   Kadota, Jun ichi ^c   Rubin, Bruce K ^b   Izuhara, Kenji ^a  

^a SAGA UNIVERSITY   (Japan)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OITA UNIVERSITY   (Japan)

^d Tenshindo Hetsugi Hospital   (Japan)

^e TEIKYO UNIVERSITY   (Japan)

Author keywords

Asthma; Fibroblast; IL 13; Macrolide; Periostin

Indexed keywords

CLARITHROMYCIN; ERYTHROMYCIN; INTERLEUKIN 12; JOSAMYCIN; SCLEROPROTEIN; STAT6 PROTEIN; TRANSCRIPTION FACTOR RUNX2; CELL ADHESION MOLECULE; INTERLEUKIN 13; POSTN PROTEIN, HUMAN;

ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; DEFENSE MECHANISM; DNA MICROARRAY; DOWN REGULATION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; GENE REPRESSION; HUMAN; HUMAN CELL; IMMUNOMODULATION; LUNG FIBROBLAST; POLYMERASE CHAIN REACTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; BIOSYNTHESIS; CELL LINE; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; DRUG INTERACTION; FIBROBLAST; LUNG; METABOLISM; PHYSIOLOGY;

CELL ADHESION MOLECULES; CELL LINE; CLARITHROMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG INTERACTIONS; FIBROBLASTS; HUMANS; INTERLEUKIN-13; LUNG;

EID: 85013350253     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/s12931-017-0519-8     Document Type: Article

References (30)

1. Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med. 1998;157:1829-32.
2. Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev. 2010;23:590-615.
3. 2-integrins (CD11b/CD18) expression, interleukin-8 release and intracellular oxidative metabolism in neutrophils. Respir Med. 2000;94:654-60.
4. Kadota J, Sakito O, Kohno S, Sawa H, Mukae H, Oda H, et al. A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis. Am Rev Respir Dis. 1993;147:153-9.
5. Shimizu T, Shimizu S, Hattori R, Gabazza EC, Majima Y. In vivo and in vitro effects of macrolide antibiotics on mucus secretion in airway epithelial cells. Am J Respir Crit Care Med. 2003;168:581-7.
6. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper Jr JA, Criner GJ, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365:689-98.
7. Southern KW, Barker PM, Solis-Moya A, Patel L. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev. 2012;11:Cd002203.
8. Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA. 2013;309:1251-9.
9. Komiya K, Kurashima A, Ihi T, Nagai H, Matsumoto N, Mizunoe S, et al. Long-term, low-dose erythromycin monotherapy for Mycobacterium avium complex lung disease: a propensity score analysis. Int J Antimicrob Agents. 2014;44:131-5.
10. Yamaya M, Azuma A, Tanaka H, Takizawa H, Chida K, Taguchi Y, et al. Inhibitory effects of macrolide antibiotics on exacerbations and hospitalization in chronic obstructive pulmonary disease in Japan: a retrospective multicenter analysis. J Am Geriatr Soc. 2008;56:1358-60.
11. Reiter J, Demirel N, Mendy A, Gasana J, Vieira ER, Colin AA, et al. Macrolides for the long-term management of asthma--a meta-analysis of randomized clinical trials. Allergy. 2013;68:1040-9.
12. Jia G, Erickson RW, Choy DF, Mosesova S, Wu LC, Solberg OD, et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol. 2012;130:647-54. e10.
13. Blanchard C, Mingler MK, McBride M, Putnam PE, Collins MH, Chang G, et al. Periostin facilitates eosinophil tissue infiltration in allergic lung and esophageal responses. Mucosal Immunol. 2008;1:289-96.
14. Sidhu SS, Yuan S, Innes AL, Kerr S, Woodruff PG, Hou L, et al. Roles of epithelial cell-derived periostin in TGF-β activation, collagen production, and collagen gel elasticity in asthma. Proc Natl Acad Sci USA. 2010;107:14170-5.
15. Naik PK, Bozyk PD, Bentley JK, Popova AP, Birch CM, Wilke CA, et al. Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2012;303:L1046-56.
16. Yuyama N, Davies DE, Akaiwa M, Matsui K, Hamasaki Y, Suminami Y, et al. Analysis of novel disease-related genes in bronchial asthma. Cytokine. 2002;19:287-96.
17. Izuhara K, Arima K, Ohta S, Suzuki S, Inamitsu M, Yamamoto K. Periostin in allergic inflammation. Allergol Int. 2014;63:143-51.
18. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365:1088-98.
19. McCarty JM. Clarithromycin in the management of community-acquired pneumonia. Clin Ther. 2000;22:281-94.
20. Tanabe T, Kanoh S, Tsushima K, Yamazaki Y, Kubo K, Rubin BK. Clarithromycin inhibits interleukin-13-induced goblet cell hyperplasia in human airway cells. Am J Respir Cell Mol Biol. 2011;45:1075-83.
21. Shoda T, Futamura K, Kobayashi F, Saito H, Matsumoto K, Matsuda A. Cell type-dependent effects of corticosteroid on periostin production by primary human tissue cells. Allergy. 2013;68:1467-70.
22. Takayama G, Arima K, Kanaji T, Toda S, Tanaka H, Shoji S, et al. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol. 2006;118:98-104.
23. Masuoka M, Shiraishi H, Ohta S, Suzuki S, Arima K, Aoki S, et al. Periostin promotes chronic allergic inflammation in response to Th2 cytokines. J Clin Invest. 2012;122:2590-600.
24. Izuhara K, Arima K, Kanaji S, Ohta S, Kanaji T. IL-13: a promising therapeutic target for bronchial asthma. Curr Med Chem. 2006;13:2291-8.
25. Chandriani S, DePianto DJ, N'Diaye EN, Abbas AR, Jackman J, Bevers 3rd J, et al. Endogenously expressed IL-13Rα2 attenuates IL-13-mediated responses but does not activate signaling in human lung fibroblasts. J Immunol. 2014;193:111-9.
26. Suzaki I, Kawano S, Komiya K, Tanabe T, Akaba T, Asano K, et al. Inhibition of IL-13-induced periostin in airway epithelium attenuates cellular protein expression of MUC5AC. Respirology. 2016;22:93-100.
27. So EY, Oh J, Jang JY, Kim JH, Lee CE. Ras/Erk pathway positively regulates Jak1/STAT6 activity and IL-4 gene expression in Jurkat T cells. Mol Immunol. 2007;44:3416-26.
28. Shinkai M, Foster GH, Rubin BK. Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2006;290:L75-85.
29. Blaauboer ME, Boeijen FR, Emson CL, Turner SM, Zandieh-Doulabi B, Hanemaaijer R, et al. Extracellular matrix proteins: a positive feedback loop in lung fibrosis? Matrix Biol. 2014;34:170-8.
30. Yu C, Azuma A, Li Y, Wang C, Abe S, Usuki J, et al. EM703, a new derivative of erythromycin, inhibits transforming growth factor-beta signaling in human lung fibroblasts. Exp Lung Res. 2008;34:343-54.